Patients with known hepatic cirrhosis or severe pre-existing hepatic impairment are not eligible
Have moderate or severe cardiovascular disease:
Moderate or severe heart valve function defect including moderate or severe valve stenosis or regurgitation.
Severe or moderate hepatic impairment
Contraindication to hepatic arteriography (e.g. hepatic artery dissection and/or thrombosis, uncorrectable coagulopathy, severe allergy to iodinated contrast, severe vascular disease precluding safe hepatic artery catheterization)
Have moderate or severe cardiovascular disease.
Active or severe hepatic or renal disease.
Patient may not have severe hepatic disease (direct bilirubin greater than 3 mg/dl OR aspartate aminotransferase [AST] greater than 500 IU/L), unless hepatic injury is due to LCH
Known hepatic cirrhosis or severe pre-existing hepatic impairment
Known hepatic cirrhosis or severe pre-existing hepatic impairment
Has known hepatic cirrhosis or severe preexisting hepatic impairment.
Liver cirrhosis or severe hepatic impairment with function test 3 times above ULN.
Patients with known moderate or severe hepatic impairment, active hepatitis A, B, and/or C infection, due to the difficulty that would be faced in assessing the attribution of any events of hepatic toxicity while on cabozantinib therapy
Known hepatic cirrhosis or severe pre-existing hepatic impairment
Have moderate or severe cardiovascular disease.
Have moderate or severe cardiovascular disease.
Have moderate or severe cardiovascular disease:
Subjects with moderate-severe renal disease
Clinical evidence of severe hepatic impairment
Known hepatic cirrhosis or severe pre-existing hepatic impairment
Moderate to severe hepatic impairment.
Known hepatic cirrhosis or severe pre-existing hepatic impairment
28 or more reported moderate-to-very severe hot flashes per week
Known hepatic cirrhosis or severe pre existing hepatic impairment.
Moderate or severe hepatic impairment
Patients with moderate to severe renal impairment.
Patients with moderate or severe cardiac disease:
Moderate hepatic impairment with total bilirubin greater than 1.5 to less than or equal to 3.0 × ULN
Severe cardiovascular or hepatic disease
Moderate to severe steroid-refractory cGVHD as defined by all following criteria:
Known hepatic cirrhosis or severe pre-existing hepatic impairment
Subjects with severe hepatic impairment\r\n* Bilirubin > 3 x ULN, regardless of any level of ALT
Have moderate or severe cardiac disease:
Moderate or severe cardiovascular disease
Severe (CTCAE v 4.03 grade 3 or higher) concurrent hepatic impairment, renal impairment, heart disease, hematological disease, respiratory disease, or metabolic disease
Severe renal impairment.
Severe hepatic impairment.
Moderate to severe hepatic impairment
Central nervous system injury or severe neurological impairment
Participants with moderate hepatic impairment: total bilirubin must be > 1.5 to 3 x ULN with any ALT level.
Participants with severe hepatic impairment: total bilirubin must be > 3 x ULN with any ALT level.
Moderate to severe aortic or mitral stenosis or other valvulopathy (ongoing).
Known hepatic impairment including cirrhosis, known renal impairment including renal insufficiency or glomerulonephritis and severe cerebral or peripheral vascular disease;
Known hepatic cirrhosis or severe pre-existing hepatic impairment
Severe hepatic impairment
Have severe hepatic impairment, severe renal impairment, or end-stage renal disease as determined by the treating physician
Patients with severe hepatic impairment
Severe visual or auditory impairment
Severe renal impairment as measured eGFR less than 30 per institutional laboratory
Have moderate to severe levels of fatigue
Megacolon or moderate to severe ileus
Moderate to severe fatigue (>= 4 on BFI)
Moderate to severe sun damage
Patient has a history of severe renal or hepatic impairment, severe bone marrow suppression, or systemic infection
Patients with evidence of moderate or severe cardiac valvular disease on echocardiogram
Moderate or severe aortic stenosis
Have moderate or severe cardiac disease:
Known moderate to severe aortic stenosis, moderate to severe mitral stenosis, or other valvulopathy (ongoing).
Clinical diagnosis of chronic hepatic impairment that is stable with no acute worsening of liver failure within one month prior to enrollment. Hepatic impairment will be assessed as per National Cancer Institute Organ Dysfunction Working Group Criteria (NCI-ODWG) schema and will fall into one of the following three categories: